Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in korean patients with major depressive disorder

Eun Soo Won, Hun Soo Chang, Hwa Young Lee, Byung-Joo Ham, Min-Soo Lee

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: Various studies have shown that short (s)/long (l) polymorphisms of the serotonin transporter-linked polymorphic region (5-HTTLPR) might predict treatment outcome to selective serotonin reuptake inhibitors. The purpose of this study was to evaluate the association between 5-HTTLPR and clinical response to escitalopram treatment in Korean subjects with major depressive disorder. Methods: One hundred and fifteen Korean patients diagnosed with major depressive disorder were evaluated during 8 weeks of escitalopram treatment at a dose of 5-20 mg/day. Patients were genotyped for 5-HTTLPR using polymerase chain reaction. Clinical symptoms were evaluated by the 21-item Hamilton Depression Rating (HAMD-21) scale during the 8 weeks of treatment. Results: Therapeutic response to antidepressant escitalopram was better in s allele carriers (ss, sl) than in l allele homozygotes (ll) at 8 weeks of treatment (OR = 6.24, p = 0.026). The proportion of s allele carriers in responders was higher than that in non-responders (96.6 vs. 85.7%). The percentile decline in HAMD-21 in s allele carriers (59.86 ± 3.23%) was larger than that in HAMD-21 in l allele homozygotes (43.13 ± 11.49%; p = 0.029). However, 5-HTTLPR genotypes were not significantly associated with remission (p > 0.05). Conclusions: Our results show that treatment response to escitalopram at 8 weeks was moderated by 5-HTTLPR, with better response rates for s allele carriers than for l allele homozygotes. Although the role of 5-HTTLPR as a definite predictor of selective serotonin reuptake inhibitor treatment response cannot be confirmed from current results, they do suggest a trend for better response in s allele carriers.

Original languageEnglish
Pages (from-to)221-229
Number of pages9
JournalNeuropsychobiology
Volume66
Issue number4
DOIs
Publication statusPublished - 2012 Nov 1

Fingerprint

Serotonin Plasma Membrane Transport Proteins
Citalopram
Major Depressive Disorder
Antidepressive Agents
Alleles
Homozygote
Serotonin Uptake Inhibitors
Therapeutics
Genotype
Depression
Polymerase Chain Reaction

Keywords

  • Escitalopram treatment response
  • Major depressive disorder
  • Serotonin transporter-linked polymorphic region

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuropsychology and Physiological Psychology
  • Biological Psychiatry

Cite this

Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in korean patients with major depressive disorder. / Won, Eun Soo; Chang, Hun Soo; Lee, Hwa Young; Ham, Byung-Joo; Lee, Min-Soo.

In: Neuropsychobiology, Vol. 66, No. 4, 01.11.2012, p. 221-229.

Research output: Contribution to journalArticle

@article{b92986c276924da8a9b2ace16e53437e,
title = "Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in korean patients with major depressive disorder",
abstract = "Objective: Various studies have shown that short (s)/long (l) polymorphisms of the serotonin transporter-linked polymorphic region (5-HTTLPR) might predict treatment outcome to selective serotonin reuptake inhibitors. The purpose of this study was to evaluate the association between 5-HTTLPR and clinical response to escitalopram treatment in Korean subjects with major depressive disorder. Methods: One hundred and fifteen Korean patients diagnosed with major depressive disorder were evaluated during 8 weeks of escitalopram treatment at a dose of 5-20 mg/day. Patients were genotyped for 5-HTTLPR using polymerase chain reaction. Clinical symptoms were evaluated by the 21-item Hamilton Depression Rating (HAMD-21) scale during the 8 weeks of treatment. Results: Therapeutic response to antidepressant escitalopram was better in s allele carriers (ss, sl) than in l allele homozygotes (ll) at 8 weeks of treatment (OR = 6.24, p = 0.026). The proportion of s allele carriers in responders was higher than that in non-responders (96.6 vs. 85.7{\%}). The percentile decline in HAMD-21 in s allele carriers (59.86 ± 3.23{\%}) was larger than that in HAMD-21 in l allele homozygotes (43.13 ± 11.49{\%}; p = 0.029). However, 5-HTTLPR genotypes were not significantly associated with remission (p > 0.05). Conclusions: Our results show that treatment response to escitalopram at 8 weeks was moderated by 5-HTTLPR, with better response rates for s allele carriers than for l allele homozygotes. Although the role of 5-HTTLPR as a definite predictor of selective serotonin reuptake inhibitor treatment response cannot be confirmed from current results, they do suggest a trend for better response in s allele carriers.",
keywords = "Escitalopram treatment response, Major depressive disorder, Serotonin transporter-linked polymorphic region",
author = "Won, {Eun Soo} and Chang, {Hun Soo} and Lee, {Hwa Young} and Byung-Joo Ham and Min-Soo Lee",
year = "2012",
month = "11",
day = "1",
doi = "10.1159/000341876",
language = "English",
volume = "66",
pages = "221--229",
journal = "Neuropsychobiology",
issn = "0302-282X",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in korean patients with major depressive disorder

AU - Won, Eun Soo

AU - Chang, Hun Soo

AU - Lee, Hwa Young

AU - Ham, Byung-Joo

AU - Lee, Min-Soo

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Objective: Various studies have shown that short (s)/long (l) polymorphisms of the serotonin transporter-linked polymorphic region (5-HTTLPR) might predict treatment outcome to selective serotonin reuptake inhibitors. The purpose of this study was to evaluate the association between 5-HTTLPR and clinical response to escitalopram treatment in Korean subjects with major depressive disorder. Methods: One hundred and fifteen Korean patients diagnosed with major depressive disorder were evaluated during 8 weeks of escitalopram treatment at a dose of 5-20 mg/day. Patients were genotyped for 5-HTTLPR using polymerase chain reaction. Clinical symptoms were evaluated by the 21-item Hamilton Depression Rating (HAMD-21) scale during the 8 weeks of treatment. Results: Therapeutic response to antidepressant escitalopram was better in s allele carriers (ss, sl) than in l allele homozygotes (ll) at 8 weeks of treatment (OR = 6.24, p = 0.026). The proportion of s allele carriers in responders was higher than that in non-responders (96.6 vs. 85.7%). The percentile decline in HAMD-21 in s allele carriers (59.86 ± 3.23%) was larger than that in HAMD-21 in l allele homozygotes (43.13 ± 11.49%; p = 0.029). However, 5-HTTLPR genotypes were not significantly associated with remission (p > 0.05). Conclusions: Our results show that treatment response to escitalopram at 8 weeks was moderated by 5-HTTLPR, with better response rates for s allele carriers than for l allele homozygotes. Although the role of 5-HTTLPR as a definite predictor of selective serotonin reuptake inhibitor treatment response cannot be confirmed from current results, they do suggest a trend for better response in s allele carriers.

AB - Objective: Various studies have shown that short (s)/long (l) polymorphisms of the serotonin transporter-linked polymorphic region (5-HTTLPR) might predict treatment outcome to selective serotonin reuptake inhibitors. The purpose of this study was to evaluate the association between 5-HTTLPR and clinical response to escitalopram treatment in Korean subjects with major depressive disorder. Methods: One hundred and fifteen Korean patients diagnosed with major depressive disorder were evaluated during 8 weeks of escitalopram treatment at a dose of 5-20 mg/day. Patients were genotyped for 5-HTTLPR using polymerase chain reaction. Clinical symptoms were evaluated by the 21-item Hamilton Depression Rating (HAMD-21) scale during the 8 weeks of treatment. Results: Therapeutic response to antidepressant escitalopram was better in s allele carriers (ss, sl) than in l allele homozygotes (ll) at 8 weeks of treatment (OR = 6.24, p = 0.026). The proportion of s allele carriers in responders was higher than that in non-responders (96.6 vs. 85.7%). The percentile decline in HAMD-21 in s allele carriers (59.86 ± 3.23%) was larger than that in HAMD-21 in l allele homozygotes (43.13 ± 11.49%; p = 0.029). However, 5-HTTLPR genotypes were not significantly associated with remission (p > 0.05). Conclusions: Our results show that treatment response to escitalopram at 8 weeks was moderated by 5-HTTLPR, with better response rates for s allele carriers than for l allele homozygotes. Although the role of 5-HTTLPR as a definite predictor of selective serotonin reuptake inhibitor treatment response cannot be confirmed from current results, they do suggest a trend for better response in s allele carriers.

KW - Escitalopram treatment response

KW - Major depressive disorder

KW - Serotonin transporter-linked polymorphic region

UR - http://www.scopus.com/inward/record.url?scp=84867665768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867665768&partnerID=8YFLogxK

U2 - 10.1159/000341876

DO - 10.1159/000341876

M3 - Article

VL - 66

SP - 221

EP - 229

JO - Neuropsychobiology

JF - Neuropsychobiology

SN - 0302-282X

IS - 4

ER -